Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Jeong Seok | - |
dc.contributor.author | Youn, Gi Soo | - |
dc.contributor.author | Choi, Jieun | - |
dc.contributor.author | Kim, Chang-Ho | - |
dc.contributor.author | Kim, Byung Yong | - |
dc.contributor.author | Yang, Seung-Jo | - |
dc.contributor.author | Lee, Je Hee | - |
dc.contributor.author | Park, Tae-Sik | - |
dc.contributor.author | Kim, Byoung Kook | - |
dc.contributor.author | Kim, Yeon Bee | - |
dc.contributor.author | Roh, Seong Woon | - |
dc.contributor.author | Min, Byeong Hyun | - |
dc.contributor.author | Park, Hee Jin | - |
dc.contributor.author | Yoon, Sang Jun | - |
dc.contributor.author | Lee, Na Young | - |
dc.contributor.author | Choi, Ye Rin | - |
dc.contributor.author | Kim, Hyeong Seob | - |
dc.contributor.author | Gupta, Haripriya | - |
dc.contributor.author | Sung, Hotaik | - |
dc.contributor.author | Han, Sang Hak | - |
dc.contributor.author | Suk, Ki Tae | - |
dc.contributor.author | Lee, Do Yup | - |
dc.date.accessioned | 2022-03-18T05:40:48Z | - |
dc.date.available | 2022-03-18T05:40:48Z | - |
dc.date.created | 2022-03-18 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 2001-1326 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83767 | - |
dc.description.abstract | Background Although microbioa-based therapies have shown putative effects on the treatment of non-alcoholic fatty liver disease (NAFLD), it is not clear how microbiota-derived metabolites contribute to the prevention of NAFLD. We explored the metabolomic signature of Lactobacillus lactis and Pediococcus pentosaceus in NAFLD mice and its association in NAFLD patients. Methods We used Western diet-induced NAFLD mice, and L. lactis and P. pentosaceus were administered to animals in the drinking water at a concentration of 10(9) CFU/g for 8 weeks. NAFLD severity was determined based on liver/body weight, pathology and biochemistry markers. Caecal samples were collected for the metagenomics by 16S rRNA sequencing. Metabolite profiles were obtained from caecum, liver and serum. Human stool samples (healthy control [n = 22] and NAFLD patients [n = 23]) were collected to investigate clinical reproducibility for microbiota-derived metabolites signature and metabolomics biomarker. Results L. lactis and P. pentosaceus supplementation effectively normalized weight ratio, NAFLD activity score, biochemical markers, cytokines and gut-tight junction. While faecal microbiota varied according to the different treatments, key metabolic features including short chain fatty acids (SCFAs), bile acids (BAs) and tryptophan metabolites were analogously restored by both probiotic supplementations. The protective effects of indole compounds were validated with in vitro and in vivo models, including anti-inflammatory effects. The metabolomic signatures were replicated in NAFLD patients, accompanied by the comparable levels of Firmicutes/Bacteroidetes ratio, which was significantly higher (4.3) compared with control (0.6). Besides, the consequent biomarker panel with six stool metabolites (indole, BAs, and SCFAs) showed 0.922 (area under the curve) in the diagnosis of NAFLD. Conclusions NAFLD progression was robustly associated with metabolic dys-regulations in the SCFAs, bile acid and indole compounds, and NAFLD can be accurately diagnosed using the metabolites. L. lactis and P. pentosaceus ameliorate NAFLD progression by modulating gut metagenomic and metabolic environment, particularly tryptophan pathway, of the gut-liver axis. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | JOHN WILEY & SONS LTD | - |
dc.relation.isPartOf | CLINICAL AND TRANSLATIONAL MEDICINE | - |
dc.title | Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000759761200036 | - |
dc.identifier.doi | 10.1002/ctm2.634 | - |
dc.identifier.bibliographicCitation | CLINICAL AND TRANSLATIONAL MEDICINE, v.11, no.12 | - |
dc.description.isOpenAccess | N | - |
dc.citation.title | CLINICAL AND TRANSLATIONAL MEDICINE | - |
dc.citation.volume | 11 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Park, Tae-Sik | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | gut-liver axis | - |
dc.subject.keywordAuthor | indole | - |
dc.subject.keywordAuthor | metabolites | - |
dc.subject.keywordAuthor | microbiome | - |
dc.subject.keywordAuthor | non-alcoholic fatty liver disease | - |
dc.subject.keywordPlus | ACIDS | - |
dc.subject.keywordPlus | TRAITS | - |
dc.subject.keywordPlus | INJURY | - |
dc.subject.keywordPlus | NAFLD | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.